201 related articles for article (PubMed ID: 24302998)
1. Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermansky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects.
Lorenzi L; Tabellini G; Vermi W; Moratto D; Porta F; Notarangelo LD; Patrizi O; Sozzani S; de Saint Basile G; Latour S; Pace D; Lonardi S; Facchetti F; Badolato R; Parolini S
PLoS One; 2013; 8(11):e80131. PubMed ID: 24302998
[TBL] [Abstract][Full Text] [Related]
2. Innate immunity defects in Hermansky-Pudlak type 2 syndrome.
Fontana S; Parolini S; Vermi W; Booth S; Gallo F; Donini M; Benassi M; Gentili F; Ferrari D; Notarangelo LD; Cavadini P; Marcenaro E; Dusi S; Cassatella M; Facchetti F; Griffiths GM; Moretta A; Notarangelo LD; Badolato R
Blood; 2006 Jun; 107(12):4857-64. PubMed ID: 16507770
[TBL] [Abstract][Full Text] [Related]
3. Disruption of AP3B1 by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2.
Jones ML; Murden SL; Brooks C; Maloney V; Manning RA; Gilmour KC; Bharadwaj V; de la Fuente J; Chakravorty S; Mumford AD
BMC Med Genet; 2013 Apr; 14():42. PubMed ID: 23557002
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon-γ or interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection.
Conroy MJ; Mac Nicholas R; Grealy R; Taylor M; Otegbayo JA; O'Dea S; Mulcahy F; Ryan T; Norris S; Doherty DG
J Viral Hepat; 2015 Mar; 22(3):335-45. PubMed ID: 25186004
[TBL] [Abstract][Full Text] [Related]
5. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
6. Novel mutation in Hermansky-Pudlak syndrome type 2 with mild immunological phenotype.
Kurnik K; Bartsch I; Maul-Pavicic A; Ehl S; Sandrock-Lang K; Bidlingmaier C; Rombach N; Busse A; Belohradsky BH; Müller-Höcker J; Aslanidis C; Schmitz G; Zieger B
Platelets; 2013; 24(7):538-43. PubMed ID: 23215637
[TBL] [Abstract][Full Text] [Related]
7. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic.
Ferlazzo G; Thomas D; Lin SL; Goodman K; Morandi B; Muller WA; Moretta A; Münz C
J Immunol; 2004 Feb; 172(3):1455-62. PubMed ID: 14734722
[TBL] [Abstract][Full Text] [Related]
8. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
Wu D; Thomas A; Fromm JR
Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell activity and dysfunction in Hermansky-Pudlak syndrome.
Gil-Krzewska A; Murakami Y; Peruzzi G; O'Brien KJ; Merideth MA; Cullinane AR; Gahl WA; Coligan JE; Gochuico BR; Krzewski K
Br J Haematol; 2017 Jan; 176(1):118-123. PubMed ID: 27766632
[TBL] [Abstract][Full Text] [Related]
10. Circulating NK cells and their subsets in Behçet's disease.
Hasan MS; Ryan PL; Bergmeier LA; Fortune F
Clin Exp Immunol; 2017 May; 188(2):311-322. PubMed ID: 28170096
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Visser L; Rutgers B; Diepstra A; van den Berg A; Sattarzadeh A
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999289
[TBL] [Abstract][Full Text] [Related]
12. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver.
Harmon C; Robinson MW; Fahey R; Whelan S; Houlihan DD; Geoghegan J; O'Farrelly C
Eur J Immunol; 2016 Sep; 46(9):2111-20. PubMed ID: 27485474
[TBL] [Abstract][Full Text] [Related]
13. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2.
Jessen B; Bode SF; Ammann S; Chakravorty S; Davies G; Diestelhorst J; Frei-Jones M; Gahl WA; Gochuico BR; Griese M; Griffiths G; Janka G; Klein C; Kögl T; Kurnik K; Lehmberg K; Maul-Pavicic A; Mumford AD; Pace D; Parvaneh N; Rezaei N; de Saint Basile G; Schmitt-Graeff A; Schwarz K; Karasu GT; Zieger B; Zur Stadt U; Aichele P; Ehl S
Blood; 2013 Apr; 121(15):2943-51. PubMed ID: 23403622
[TBL] [Abstract][Full Text] [Related]
14. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
15.
Scorpio DG; Choi KS; Dumler JS
Front Immunol; 2018; 9():710. PubMed ID: 29686681
[TBL] [Abstract][Full Text] [Related]
16. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
17. Imbalance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation.
Yamagiwa S; Sato Y; Ichida T; Setsu T; Tominaga K; Kamimura H; Tsuchiya A; Takamura M; Matsuda Y; Aoyagi Y
Biomed Res; 2014; 35(3):177-84. PubMed ID: 24942856
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression.
Zahran AM; Abdel-Rahim MH; Elsayh KI; Hassanien MM; Mahran SA; Hetta HF
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):161-169. PubMed ID: 30944972
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens.
White MJ; Nielsen CM; McGregor RH; Riley EH; Goodier MR
Immunology; 2014 May; 142(1):140-50. PubMed ID: 24843874
[TBL] [Abstract][Full Text] [Related]
20. Dysfunction of CD3
Tahrali I; Kucuksezer UC; Altintas A; Uygunoglu U; Akdeniz N; Aktas-Cetin E; Deniz G
Clin Immunol; 2018 Aug; 193():88-97. PubMed ID: 29448007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
